case_images: PMC11446895_01
case_images: Clinical management of the patient. EIA, exercise-induced anaphylaxis; ICS + LABA, inhaled corticosteroids + long acting beta agonists; SC, subcutaneous injection.
case_images: falgy-05-1453873-g001.jpg
case_images: PMC11446895_01_falgy-05-1453873-g001.jpg
case_images: F1
case_images: The first episode occurred approximately 4 weeks into treatment, and the second episode occurred approximately 8 weeks into treatment (Figure 1). The patient was initiated on omalizumab injections of 300 mg every 4 weeks starting in March 2022 (Figure 1). Table 1 and Supplementary Figure S1. The FENO level and variables of pulmonary function testing were also monitored during the follow-up period (Supplementary Figure S2).